Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 35.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 310,650 shares of the company’s stock after buying an additional 80,536 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned about 0.52% of Protagonist Therapeutics worth $11,963,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Nisa Investment Advisors LLC increased its holdings in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after buying an additional 295 shares during the period. Louisiana State Employees Retirement System increased its holdings in Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after buying an additional 300 shares during the period. KBC Group NV increased its holdings in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after buying an additional 737 shares during the period. Moran Wealth Management LLC increased its holdings in Protagonist Therapeutics by 6.2% in the 4th quarter. Moran Wealth Management LLC now owns 15,961 shares of the company’s stock worth $616,000 after buying an additional 931 shares during the period. Finally, FNY Investment Advisers LLC acquired a new position in Protagonist Therapeutics in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now owns 540,260 shares in the company, valued at approximately $20,627,126.80. This trade represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the transaction, the insider now owns 83,892 shares in the company, valued at $4,676,140.08. The trade was a 26.67 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,776 shares of company stock worth $3,368,010. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock opened at $54.78 on Friday. The company’s fifty day moving average price is $39.63 and its 200 day moving average price is $42.24. Protagonist Therapeutics, Inc. has a 1 year low of $24.22 and a 1 year high of $60.60. The stock has a market capitalization of $3.36 billion, a P/E ratio of 20.59 and a beta of 2.34.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on PTGX shares. JPMorgan Chase & Co. raised their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $54.00 price objective on shares of Protagonist Therapeutics in a research note on Monday, March 10th. The Goldman Sachs Group dropped their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a research note on Monday, February 24th. BMO Capital Markets raised their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $61.22.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.